Long-Term ContinuousversusIntermittent Cyclosporin: Therapy for Psoriasis-Reference-Cited by-同舟云学术

Long-Term ContinuousversusIntermittent Cyclosporin: Therapy for Psoriasis

Published:2003-04 Issue:4 Volume:30 Page:290-298
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Ohtsuki Mamitaro¹,Nakagawa Hidemi¹,Sugai Junichi²,Ozawa Akira²,Ohkido Muneo²,Nakayama Juichiro³,Hanada Jiro⁴,Morimoto Yosuke⁴,Jimbow Kowichi⁴,Horikoshi Takashi⁵,Kitahara Hiroto⁶,Tamaki Kunihiko⁶,Urabe Kazunori⁷,Hori Yoshiaki⁷

Affiliation:

1. Jichi Medical School; Tochigi Japan

2. Tokai University; Kanagawa Japan

3. Fukuoka University; Fukuoka Japan

4. Sapporo Medical College; Hokkaido Japan

5. Omotesando Clinic; Tokyo Japan

6. University of Tokyo; Tokyo Japan

7. Kyushu University; Fukuoka Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1346-8138.2003.tb00390.x/fullpdf

Reference22 articles.

1. Cyclosporine for psoriasis;Mueller;N Engl J Med,1979

2. A consensus report: Cyclosporin A therapy for psoriasis;Br J Dermatol,1990

3. Guidelines for management of patients with psoriasis;Williams;BMJ,1991

4. Treatment of psoriasis;Greaves;N Engl J Med,1995

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential of Cyclosporine in the Treatment of Psoriasis: Trends, Scope and Relevance Providing Newer Insights Into Immune Mechanisms;Current Dermatology Reports;2024-06-21

2. Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients;Expert Opinion on Drug Metabolism & Toxicology;2024-03-28

3. Therapy of PsO in Special Subsets of Patients;Biomedicines;2022-11-10

4. Malignancy risk of non‐biologic immunosuppressive therapies: A review of the literature with evidence‐based treatment recommendations;Experimental Dermatology;2022-07-27

5. Fixed-Combination Halobetasol Propionate/Tazarotene Lotion for Psoriasis in Patients With 3%–5% Affected Body Surface Area;Journal of Drugs in Dermatology;2021-07-01